



Addendum to:
**UKHSA Live attenuated influenza vaccine nasal spray suspension (LAIV) Patient
Group Direction (PGD), v15.0 GOV-18720**

This document provides an addendum to the [UKHSA LAIV PGD v15.0 GOV-18720](#), valid from 1 September 2025 to 1 April 2026.

In the section for 'Name, strength and formulation of drug', on page 13, the formula of the active strains has been updated below to align with the current SPC (21 July 2025) published on 23 July 2025.

Name, strength and formulation of drug, Page 13

Live attenuated influenza vaccine nasal spray suspension (0.2ml):

Fluenz® nasal spray suspension, each 0.2ml dose contains:

Reassortant influenza virus (live attenuated) of the following three strains:

A/ Victoria/4897/2022 (H1N1)pdm09 - like strain (A/ Norway/31694/2022, MEDI 369815)	$10^{7.0 \pm 0.5}$ FFU
--	------------------------

A/Croatia/10136RV/2023 (H3N2) - like strain (A/Perth/722/2024, MEDI 392611)	$10^{7.0 \pm 0.5}$ FFU
--	------------------------

B/ Austria/1359417/2021 - like strain (B/ Austria/1359417/2021, MEDI 355292)	$10^{7.0 \pm 0.5}$ FFU
---	------------------------

For the full details of the formulation see the [SPC](#).

The vaccine may contain traces of the following substances: egg proteins (e.g. ovalbumin) and gentamicin. The maximum amount of ovalbumin is less than 0.024 micrograms per 0.2 ml dose (0.12 micrograms per ml), see section 4.3 of the [SPC](#).

Background



The LAIV PGD v15.0 GOV-18720 was published on 1st July 2025, as per national flu immunisation programme plan 2025 to 2026 programme timelines. The PGD had a final check on 30th June 2025 before publishing and it aligned with the Fluenz® SPC dated 6 June 2025 which was available on the EMC site at the time. Since the publication of the PGD, the SPC has gone through an update on 21 July 2025 to the 'Qualitative and

quantative composition' section has been updated with the formula of the active strains.
The updated SPC was published on the EMC on 23 July 2025.

The addendum has been provided to the PGD to inform of the updated active strains.

UKHSA approval and ratification

This addendum is approved by the following health professionals on behalf of UKHSA:

	Name	Signature	Date
Pharmacist (Lead Author)	Suki Hunjunt Lead Pharmacist Immunisation Programmes, UKHSA		6 August 2025
Doctor	Alex Allen Consultant Epidemiologist Chief Medical Advisor, UKHSA Deputising for Jamie Lopez-Bernal Consultant Epidemiologist Chief Medical Advisor, UKHSA		6 August 2025
Registered Nurse (Chair of Expert Panel)	Greta Hayward Consultant Midwife for Immunisation Programmes, UKHSA		6 August 2025

This addendum has been approved by the PGD Expert Panel ([Appendix 1](#)) and UKHSA PGD Working Group and ratified by the Medicines Governance Committee.

Organisational authorisations

[NHS England – London] authorises the continued use of Live attenuated influenza vaccine nasal spray suspension (LAIV) Patient Group Direction (PGD), v15.0 GOV-18720 with this addendum by the services or providers listed below

Organisational approval (legal requirement)			
Role	Name	Sign	Date
Chief Nurse, NHS England – London	Karen Bonner		12/08/2025

Appendix 1

UKHSA Live attenuated influenza vaccine nasal spray suspension (LAIV) Patient Group Direction (PGD) Expert Panel

Nicholas Aigbogun	Consultant in Communicable Disease Control, Yorkshire and Humber Health Protection Team, UKHSA
Jessica Baldasera	Health Protection Practitioner, North East Health Protection Team Regions Directorate, UKHSA
Helen Beynon	Clinical Advisor, Immunisation Clinical Advice Response Service (CARS), NHS England London
Alison Campbell	Screening and Immunisation Coordinator, Public Health Commissioning NHS England (NHS England) Midlands
Naveen Dosanjh	Senior Clinical Advisor – Vaccinations, NHS England
Helen Eley	Lead Immunisation Nurse Specialist, Immunisation Programmes, UKHSA
Jane Freeguard	Deputy Director of Vaccination – Medicines and Pharmacy NHS England
Rosie Furner	Advanced Specialist Pharmacist - Medicines Governance, Specialist Pharmacist Services (SPS)
Ed Gardner	Advanced Paramedic Practitioner/Emergency Care Practitioner, Medicines Manager, Proactive Care Lead
Shilan Ghafoor	Medicines Governance Lead Pharmacist, UKHSA
Elizabeth Lockett	Senior Screening and Immunisation Manager, Screening and Immunisation Team – Kent and Medway, NHS England South East
Briony Mason	Vaccination Manager, Professional Midwifery Advocate, Vaccination and Screening, NHS England, West Midlands
Vanessa MacGregor	Consultant in Communicable Disease Control, East Midlands Health Protection Team, UKHSA
Tushar Shah	Lead Pharmacy Adviser, NHS England London